CHRNA4 and Parkinson disease: Imaging studies on patients with PD have demonstrated a loss of striatal binding sites for 5‐[125I]‐A‐85380, a novel nAChR ligand interacting predominantly with the α4β2 subtype, that closely parallels the loss of nigrostriatal dopaminergic markers [77].